These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15619355)

  • 1. [The clinical application of prothrombin time and coagulation factors in liver diseases].
    Li Q; Jia JD; Wang BE
    Zhonghua Gan Zang Bing Za Zhi; 2004 Dec; 12(12):767-8. PubMed ID: 15619355
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of plasma transfusions on the prothrombin time and clotting factors in liver disease.
    Spector I; Corn M; Ticktin HE
    N Engl J Med; 1966 Nov; 275(19):1032-7. PubMed ID: 5923337
    [No Abstract]   [Full Text] [Related]  

  • 3. [The effect of various doses of gamma-aminobutyric acid, adrenaline and insulin on coagulation time, prothrombin time and the prothromboplastic activity of rat blood].
    Karagezian KG; Saakian SS
    Ukr Biokhim Zh; 1967; 39(4):424-9. PubMed ID: 5603095
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diagnosis of prothrombin synthesis disorders in liver diseases].
    Tilsner V
    Med Welt; 1975 Nov; 26(47):2136-8. PubMed ID: 1196106
    [No Abstract]   [Full Text] [Related]  

  • 5. Vitamine K-dependent coagulation factors in hepatobiliary diseases.
    Okabe K
    Nihon Ketsueki Gakkai Zasshi; 1982 Jul; 45(4):834-9. PubMed ID: 7136470
    [No Abstract]   [Full Text] [Related]  

  • 6. Coagulation abnormalities in patients who have liver disease.
    Trotter JF
    Clin Liver Dis; 2006 Aug; 10(3):665-78, x-xi. PubMed ID: 17162234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The clinical significance of blood coagulation analyses for the evaluation of liver diseases].
    Kopp I; Gerhartz H
    Arch Klin Med; 1966; 212(2):97-128. PubMed ID: 5974652
    [No Abstract]   [Full Text] [Related]  

  • 8. [Behavior of prothrombin complex and its factors after phenobarbital and glutethimide administration].
    Ghidini O; Recaldin E; Campo G; Tomasi A; Battocchia A; Baratta PF
    G Clin Med; 1971 Dec; 52(12):875-87. PubMed ID: 5151876
    [No Abstract]   [Full Text] [Related]  

  • 9. Inventory of exogenous hemostatic factors affecting the prothrombin activating pathways. For the Registry of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
    Stocker K
    Thromb Haemost; 1994 Feb; 71(2):257-60. PubMed ID: 8191409
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical meanings of the coagulation and fibrolysis tests in liver diseases (author's transl)].
    Okabe K
    Rinsho Byori; 1980 Jan; 28(1):3-9. PubMed ID: 7373872
    [No Abstract]   [Full Text] [Related]  

  • 11. Coagulation factors in relation to liver diseases, especially cirrhosis.
    Gupta OP
    J Indian Med Assoc; 1965 Dec; 45(12):643-5. PubMed ID: 5850548
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparison of prothrombin activity and concentration in various liver conditions].
    Oehler G; Bleyl H; Bischoff B; Henk R
    Verh Dtsch Ges Inn Med; 1974; 80():1452-5. PubMed ID: 4217982
    [No Abstract]   [Full Text] [Related]  

  • 13. Activation of prothrombin by ASP, a serine protease released from Aeromonas sobria.
    Nitta H; Kobayashi H; Irie A; Baba H; Okamoto K; Imamura T
    FEBS Lett; 2007 Dec; 581(30):5935-9. PubMed ID: 18067862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood coagulation changes in hepatic failure].
    Villalobos J; Pizzuto J; Lisker R
    Gac Med Mex; 1968 Feb; 98(2):187-94. PubMed ID: 5738268
    [No Abstract]   [Full Text] [Related]  

  • 15. [Correlation between the thrombotest and prothrombin time in normal and pathological states].
    Plesch S; Vallimitjana V; Mercier A; Cosentino JJ
    Medicina (B Aires); 1966; 26(4):189-97. PubMed ID: 5981791
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
    Ostermann H; Haertel S; Knaub S; Kalina U; Jung K; Pabinger I
    Thromb Haemost; 2007 Oct; 98(4):790-7. PubMed ID: 17938803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial.
    Testa L; Van Gaal W; Biondi-Zoccai G; Abbate A; Trotta G; Agostoni P
    Eur Heart J; 2007 Jul; 28(14):1782-3; author reply 1783. PubMed ID: 17478456
    [No Abstract]   [Full Text] [Related]  

  • 18. Hemostatic abnormalities and liver diseases.
    Wada H; Usui M; Sakuragawa N
    Semin Thromb Hemost; 2008 Nov; 34(8):772-8. PubMed ID: 19214915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver disease, coagulation testing, and hemostasis.
    Ng VL
    Clin Lab Med; 2009 Jun; 29(2):265-82. PubMed ID: 19665678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment.
    Meeks SL; Abshire TC
    Haemophilia; 2008 Nov; 14(6):1159-63. PubMed ID: 19141155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.